Skip to main content
enGene Holdings Inc. logo

enGene Holdings Inc. — Investor Relations & Filings

Ticker · ENGN ISIN · CA29286M1059 LEI · 529900NE5JFN74BYXQ13 US Manufacturing
Filings indexed 224 across all filing types
Latest filing 2026-05-07 Regulatory Filings
Country CA Canada
Listing US ENGN

About enGene Holdings Inc.

https://engene.com/

enGene Holdings Inc. is a clinical-stage biotechnology company developing non-viral gene therapies. The company's proprietary platform is designed for the local delivery of DNA-based immunotherapies directly to mucosal tissues and other organs. Its lead product candidate, EG-70 (detalimogene voraplasmid), is an intravesical therapy being evaluated for the treatment of high-risk, BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). The therapeutic approach aims to stimulate a patient's own immune system to attack tumor cells. By avoiding viral vectors, enGene seeks to create re-dosable genetic medicines that can be administered without the complexities and potential immunogenicity associated with viral-based systems, with the goal of making gene-based treatments more accessible.

Recent filings

Filing Released Lang Actions
8-K - enGene Therapeutics Inc. (0001980845) (Filer)
Regulatory Filings
2026-05-07 English
8-K - enGene Therapeutics Inc. (0001980845) (Filer)
Regulatory Filings
2026-04-09 English
S-3 - ENGENE HOLDINGS INC. (0001980845) (Filer)
Registration Form
2026-02-19 English
10-K/A - ENGENE HOLDINGS INC. (0001980845) (Filer)
Annual Report FY 2025
2026-02-19 English
SCHEDULE 13G Filing
Major Shareholding Notification
2026-02-17 English
SCHEDULE 13G/A Filing
Major Shareholding Notification
2026-02-17 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.